正高级职称人员

基本介绍

李义平 / Yiping Li 教授
分子病毒学与抗病毒药物 / Molecular Virology
博士导师,硕士导师
病毒学/Virology +86 20 8733 5085
广州市中山二路74号,510080 / Medical Research Building, Sun Yat-sen University North Campus, 74 Zhongshan 2nd Rd., Guangzhou, 510080 China
lyiping@mail.sysu.edu.cn

个人简介:

国家“青年千人计划”入选者,中山大学中山医学院人类病毒学研究所教授,病毒性肝炎研究组负责人。2004年获得中国农业大学生物学院生物化学与分子生物学(分子病毒学研究方向)博士学位,博士学习期间到丹麦皇家兽医研究所(现丹麦技术大学国家兽医研究所)和德国Friedrich-Loeffler研究所学习一年。2004和2006-2007年间,在丹麦技术大学国家兽医研究所分别做项目研究员(Project Researcher)和博士后。2005年,到加拿大萨斯喀彻温大学疫苗与传染病研究所做博士后,开始从事丙型肝炎病毒(hepatitis C virus, HCV)研究;2008-2014年1月,在丹麦哥本哈根大学Hvidovre医院传染病与临床研究中心和医学与健康科学学院CO-HEP研究组继续HCV的研究,任博士后和资深研究员(Senior Investigator)。2014年1月,获中山大学“百人计划二期”和广东省“引进创新科研团队项目”子项目启动经费支持,全职回中山医学院工作,建立病毒性肝炎研究组。

李义平教授长期从事病毒学研究工作,特别是在HCV的分子生物学、细胞感染模型和抗病毒药物的研究上,取得系列重要研究成果。探索出一套系统的新方法,鉴定出一组关键突变,建立了新型全长HCV基因1a型TNcc克隆,2a型J6cc克隆和2b型J8cc克隆等,并证明这些感染性HCV克隆对主要临床抗病毒药物反应的浓度依赖性和基因型特异性。这些成果开辟了建立HCV细胞感染模型的新途径。此外,还建立了基于JFH1的基因1-6型5’UTR-NS2和5’UTR-NS5A的嵌合体细胞感染模型,并证明HCV 5’UTR茎环结构I(SLI)的功能对基因1-6型病毒的必须性。证明HCV基因1-6型的感染对宿主微小RNA(microRNA)miR-122的依赖性;发现宿主细胞RNA和HCV本身基因序列有功能的插入到HCV 5’UTR SLI,并降低miR-122沉默对HCV感染的抑制效果,指出以miR-122为靶点的单方治疗可能遇到病毒逃逸的机理。

在HCV研究上的主要成果最近发表在PNAS,Gastroenterology,Hepatology, PLoS Pathogens, Journal of Virology和Virology等重要期刊上。

目前正在进行HCV和登革病毒的分子病毒学与抗感染免疫及药物研究工作。

课题组招聘研究员,副研究员和博士后,欢迎有志从事分子病毒学和抗病毒免疫的同行联系加入研究组。中山医学院、人类病毒学研究所和本研究组有良好的研究平台和科研环境。课题组还有非常好的未来发展空间!



Yiping Li, Ph.D., Professor of Molecular Virology,  Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University (SYSU), Guangzhou, China. Dr. Yiping Li received Ph.D. degree in Biochemistry and Molecular Biology from China Agricultural University, Beijing, China. From 2003 to 2004 and 2006 to 2007, Dr. Li worked as a visiting scholar, project researcher, and postdoctoral researcher in the National Veterinary Institute, Technical University of Denmark (previous Royal Danish Veterinary Institute). In 2005, Dr. Li pursued hepatitis C virus (HCV) research in the Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada. To continue HCV research, in February 2008 Dr. Li joined the Copenhagen Hepatitis C Program (CO-HEP), Hvidovre Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. After trainings as a postdoc and senior investigator, Dr. Li took a professor position in Zhongshan School of Medicine, SYSU in January 2014.

Dr. Yiping Li’s research interests are in the infection and immunity of HCV. To HCV research, Dr. Li has made important contributions, which have included the discoveries on the host RNA insertion-mediated viral resistance to antiviral effect of miR-122 antagonism, the development of novel full-length infectious culture systems for HCV genotypes 1a, 2a and 2b, as well as chimeric culture systems for HCV genotypes 3a, 4a, 5a, and 6a. Dr. Li’s works have led to publications on well-known journals, such as PNAS, Gastroenterology, Hepatology, PLoS Pathogens, Virology. In addition, Dr. Li also worked on animal viruses and Campylobacter. Dr. Li’s research activities have produced 25 publications, 3 U.S. patent applications and 21 conference abstracts; these have included 12 first author publications (served also as corresponding author in 3 publications) and 5 oral presentations out of 13 first author abstracts in outstanding conferences.


重要学术研究成果与贡献:


学术论著与教材:

 

主要研究论文(*, 通讯作者。#,共同第一作者)  


1.   Yuan G, Liu J, Hu C, Huang H, Qi M, Wu T, Liang W, Li YP, Zhang YY, Zhou Y*. Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Guangzhou, China: Predominance of Genotype 1b and Increasing Incidence of Genotype 6a. Cellular Physiology and Biochemistry. 2017;43(2):775-787. PMID:28950254 (PubMed) 

2.   Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W*. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. Scientific Reports 2017;7(1):3976. PMID: 28638089 (PubMed) 

3.   Fang S, Su J, Liang B, Li X, Li Y, Jiang J, Huang J, Zhou B, Ning C, Li J, Ho W, Li YP, Chen H, Liang H, Ye L*. Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Scientific Reports 2017;7:44039.  PMID:28276509 (PubMed) 

4.   Li X, Li Y, Fang S, Su J, Jiang J, Liang B, Huang J, Zhou B, Zang N, Ho W, Li J, Li YP, Chen H, Ye L, Liang H*. Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-λ1 contributes to its anti-HCV activity in human hepatoma cells. Antiviral Research 2017;140:83-94. PMID:28131804 (PubMed) 

5.   Pham LV, Ramirez S, Carlsen TH, Li YP, Gottwein JM, Bukh J*. Efficient hepatitis C virus genotype 1b Core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors. Antimicrobial agents and chemotherapy 2017 24;61(6). pii: e00037-17, doi: 10.1128/AAC.00037-17. PMID:28348150 (PubMed) 

6.   Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W*. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Scientific Reports 2016;6:25224. PMID:27121372 (PubMed) 

7.   Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM*. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrobial Agents and Chemotherapy 2016;60(6):3563-78. PMID:27021330 (PubMed)  

8.   Li YP#, Van Pham L#, Uzcategui N, Bukh J. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. Journal of General Virology. 2016;97(6):1381-94. PMID:26935756 (PubMed) 

9.   Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM*. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrobial Agents and Chemotherapy. 2015;59(12):7426-36. PMID:26392503 (PubMed) 

10. Li YP#, Ramirez S#, Mikkelsen L, Bukh J*. Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. Journal of Virology. 2015;89(1):811-23. PMID: 25355880 (PubMed) 

11. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J*. Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors. Gastroenterology 2014;146(3):812-821. PMID:24262279 (PubMed) 

12. Ramirez R, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J*. Highly efficient infectious Cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology 2014;59(2):395-407. PMID:23913364 (PubMed) 

13. Scheel TKH#, Galli1 A#, Li YP, Mikkelsen LS, Gottwein JM, Bukh J*. Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathogens 2013;9(3):e1003228. PMID:23555245 (PubMed) 

14. Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TKH, Serre S, Mikkelsen L, Bukh J*. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus. Antimicrobial Agents and Chemotherapy 2013;57(3):1291-303). PMID:23274664. (PubMed) 

15. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J*. Highly efficient full-length hepatitisC virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America 2012;109(48):19757-19762. PMID:23151512 (PubMed) 

16. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J*. Robust full-length HCV genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences of the United States of America 2012;109(18):E1101-1110. PMID:22467829 (PubMed) 

17. Li YP, Ramirez S, Gottwein JM, Bukh J*. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. Virology 2011;421(2):222-234. PMID:22029937 (PubMed) 

18. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J*. MicroRNA-122 antagonism against hepatitis C virus genotype 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5'UTR. Proceedings of the National Academy of Sciences of the United States of America 2011;108(12):4991-4996. PMID:21383155 (PubMed) 

19. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J*. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. Journal of Virology 2011;85(6):2891-2906. PMID:21177811 (PubMed)  

20. Li YP*, Vegge CS, Brondsted L, Madsen M, Ingmer H, Bang DD. Campylobacter jejuni induces an anti-inflammatory response in human intestinal epithelial cells through activation of phosphatidylinositol 3-kinase/Akt pathway. Veterinary Microbiology 2011;148(1):75-83. PMID:20863633 (PubMed) 

21. Gottwein JM#, Scheel TK#, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J*. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. Journal of Virology 2010;84(10):5277-5293. PMID:20200247 (PubMed) 

22. Vegge CS, Brondsted L, Li YP, Bang DD, Ingmer H*. Energy taxis drives Campylobacter jejuni toward the most favorable conditions for growth. Applied and Environmental Microbiology 2009;75(16):5308-5314. PMID:19542337 (PubMed) 

23. Li YP*, Ingmer H, Madsen M, Bang DD. Cytokine responses in primary chicken embryo intestinal cells infected with Campylobacter jejuni strains of human and chicken origin and the expression of bacterial virulence-associated genes. BMC Microbiology 2008;8:107. PMID:18588667 (PubMed) 

24. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, Babiuk LA, Liu Q*. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. Journal of General Virology 2008;89(Pt 5):1225-1230. PMID:18420801 (PubMed) 

25. Oem JK, Jackel-Cram C, Li YP, Kang HN, Zhou Y, Babiuk LA, Liu Q*. Hepatitis C virus non-structural protein-2 activates CXCL-8 transcription through NF-kappaB. Archives of Virology 2008;153(2):293-301. PMID:18074095 (PubMed) 

26. Li YP*, Handberg KJ, Juul-Madsen HR, Zhang MF, Jorgensen PH. Transcriptional profiles of chicken embryo cell cultures following infection with infectious bursal disease virus. Archives of Virology 2007;152(3):463-478. PMID:17143781 (PubMed) 

27. Li YP, Handberg KJ*, Kabell S, Kusk M, Zhang MF, Jorgensen PH. Relative quantification and detection of different types of infectious bursal disease virus in bursa of Fabricius and cloacal swabs using real time RT-PCR SYBR green technology. Research in Veterinary Sciences 2007;82(1):126-133. PMID:16678230 (PubMed) 

28. Li YP, Kang HN, Babiuk LA, Liu Q*. Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World Journal of Gastroenterology 2006;12(44):7126-7135. PMID:17131474 (PubMed) 

29. Bang DD*, Li YP, Nielsen SN, Madsen M. Pathogenesis properties of Campylobacter jejuni isolates obtained from different sources originating from four different EU countries. International Journal of Infectious Diseases 2006;10 (Suppl.): 217. (conference article) 

30. Li YP, Bang DD, Handberg KJ*, Jorgensen PH, Zhang MF. Evaluation of the suitability of six host genes as internal control in real-time RT-PCR assays in chicken embryo cell cultures infected with infectious bursal disease virus. Veterinary Microbiology 2005;110(3-4):155-165. PMID:16159698 (PubMed) 

31. Kabell S*, Handberg KJ, Li YP, Kusk M, Bisgaard M. Detection of vvIBDV in vaccinated SPF chickens. Acta Veterinaria Scandinavica 2005;46(4):219-227. PMID:16398333 (PubMed) 

32. Li YP, Zhang MF*. Rapid pathotyping of Newcastle disease virus from allantoic fluid and organs of experimentally infected chickens using two novel probes. Archives of Virology 2004;149(6):1231-1243. PMID:15168209 (PubMed).

 

 

 

 

 

获奖及荣誉:

基金与奖励
2016: 广东省科学技术发展基金
2015: 国家自然科学基金
2015: 国家重点基础研究发展计划(973计划)
2014:广东省自然科学基金
2014.01:入选中组部“青年千人计划”
2014:丹麦Novo Nordisk研究基金
2012-2015:丹麦国家科学技术和创新研究基金-医学科学独立研究基金
2012-2014:丹麦Lundbeck 研究基金
2012:丹麦Novo Nordisk研究基金
2011-2014:丹麦国家科学技术和创新研究基金-医学科学独立研究基金
2006:英国The Houghton Trust基金
2003:英国The Houghton Trust基金
2003:丹麦国际开发署奖学金(DANIDA Fellowship)- 中丹科技合作项目基金

学术兼职:

Danish Society for Virology

其 他:


Copyright © 2010 中山大学中山医学院

联系我们:sums@mail.sysu.edu.cn

地址:中国广州市中山二路74号中山大学北校区邮政编码:510080